Samar Issa

2.6k citations

43 papers · 1.7k · 1 hit paper · h-index 15

Impact in

Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment

Papers in

Neurology 23
- CNS Lymphoma Diagnosis and Treatment 23
Genetics 19
- Chronic Lymphocytic Leukemia Research 13
- Glioma Diagnosis and Treatment 5

Co-authors: David Simpson (9 shared papers)P. Wood (8 shared papers)Kathryn S. Kolibaba (7 shared papers)John M. Burke (7 shared papers)David A. Macdonald (7 shared papers)Ian W. Flinn (7 shared papers)Tim E. Hawkins (6 shared papers)Brad S. Kahl (6 shared papers)
Journals: Blood (14 papers)Hematological Oncology (3 papers)Neuro-Oncology (3 papers)Journal of Clinical Oncology (3 papers)Annals of Oncology (2 papers)
Partner nations: New Zealand Australia United States

In The Last Decade

Samar Issa

40 papers receiving 1.7k citations

Samar Issa's Hit Papers

align trajectories log scale

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study 2014 · 468 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2014 Blood

Peers

Countries citing papers authored by Samar Issa

Since Specialization

Citations

This map shows the geographic impact of Samar Issa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samar Issa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samar Issa more than expected).

Fields of papers citing papers by Samar Issa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samar Issa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samar Issa. The network helps show where Samar Issa may publish in the future.

Co-authors

The 25 scholars most cited alongside Samar Issa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Samar Issa Line = papers co-authored together Samar Issa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, P. Wood, Tim E. Hawkins, David A. Macdonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina A. Clementi, Doreen M. Hallman, Mihaela C. Munteanu, Ling Chen, John M. Burke Hit paper breakdown →	2014	468
2	Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma Journal of Clinical Oncology ·James L. Rubenstein, Jane Fridlyand, Lauren E. Abrey, Arthur Shen, Jon Karch, Endi Wang, Samar Issa, Lloyd Earl Damon, Michael D. Prados, Michael McDermott, Joan M. O’Brien, Chris Haqq, Marc Shuman	2007	275
3	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study Journal of Clinical Oncology ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, P. Wood, Tim E. Hawkins, David A. Macdonald, David Simpson, Kathryn S. Kolibaba, Samar Issa, Julie E Chang, Judith Trotman, Doreen M. Hallman, Ling Chen, John M. Burke	2019	195
4	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study The Lancet Oncology ·Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Marc F. Durian, Gavin Cull, Harry C. Schouten, Wendy B.C. Stevens, Josée M. Zijlstra, Joke W. Baars, Marcel Nijland, Kylie D. Mason, Aart Beeker, Martin J. van den Bent, Max Beijert, Michael F Gonzales, Daphne de Jong, Jeanette K. Doorduijn	2019	170
5	Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI Clinical Cancer Research ·Matthew Joseph Wieduwilt, Francisco E. Valles, Samar Issa, Caroline M. Behler, James Q. Hwang, Michael McDermott, PATRICK A. TRESELER, Joan M. O’Brien, Marc A. Shuman, Soonmee Cha, Lloyd Earl Damon, James L. Rubenstein	2012	104
6	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study Blood ·Jorge J. Castillo, Gilad Itchaki, Jonas Paludo, Marzia Varettoni, Christian Buske, Toby Andrew Eyre, Julio César Gálvez Chávez, Kenneth H. Shain, Samar Issa, Maria Lia Palomba, Oren Pasvolsky, David Simpson, Dipti Talaulikar, Constantine S. Tam, Alessandra Tedeschi, S. M. Ansell, Lakshmi Nayak, Steven Treon	2018	77
7	Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis Hematological Oncology ·Andreas Michael Schmitt, Amanda Katherina Herbrand, Christopher Paul Fox, Katerina Bakunina, Jacoline E. C. Bromberg, Kate Cwynarski, Jeanette K. Doorduijn, A Ferreri, Gerald Illerhaus, Samar Issa, Elisabeth Schorb, Emanuele Zucca, Lars G. Hemkens, Stefan Schandelmaier, Benjamin Kasenda	2019	54
8	Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project Haematologica ·Jacoline E. C. Bromberg, Jeanette K. Doorduijn, Gerald Illerhaus, Kristoph Jahnke, Agnieszka Korfel, Lisanne Fischer, Kristina Fritsch, Outi M. Kuittinen, Samar Issa, C. van Montfort, Martin J. van den Bent	2012	46
9	Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma Annals of Oncology ·Maurilio Ponzoni, Samar Issa, Tracy T. Batchelor, James L. Rubenstein	2013	41
10	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience British Journal of Haematology ·Katharine Louise Lewis, Collin K. Chin, Kate Manos, John M Casey, Nada Hamad, Julie H. Crawford, Shir‐Jing Ho, Samar Issa, Andrew Grigg, P. Wood, Maher K. Gandhi, Bryan Do, Loretta J. Nastoupil, Eliza Anne Hawkes, C. Y. Cheah	2020	37
11	An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study Blood ·Ian W. Flinn, Richard HC van der Jagt, Brad S. Kahl, P. Wood, Tim E. Hawkins, David A. Macdonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela C. Munteanu, Regina A. Clementi, Ling Chen, John M. Burke	2012	28
12	Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial Blood ·David T. O. Yeung, Michael Philip Osborn, Deborah L. White, Susan Branford, Michael S. Kornhauser, Cassandra Slader, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Kevin Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes	2011	24
13	Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis Supportive Care in Cancer ·Sophie Hyesuk Lee, Angela Knox, Irene S. L. Zeng, Christin Coomarasamy, Hilary Anne Blacklock, Samar Issa	2012	20
14	MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma Journal of Neuro-Oncology ·Matthijs van der Meulen, Linda Dirven, Katerina Bakunina, Martin J. van den Bent, Samar Issa, Jeanette K. Doorduijn, Jacoline E. C. Bromberg	2021	17
15	Extent of radiological response does not reflect survival in primary central nervous system lymphoma Neuro-Oncology Advances ·Matthijs van der Meulen, Alida Annechien Postma, Marion Smits, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Gavin Cull, Roelien H. Enting, Marjolein van der Poel, Wendy B.C. Stevens, Dieta Brandsma, Aart Beeker, Jeanette K. Doorduijn, Samar Issa, Martin J. van den Bent, Jacoline E. C. Bromberg	2021	17
16	Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial Blood ·David T. O. Yeung, Michael Philip Osborn, Deborah L. White, Susan Branford, Michael S. Kornhauser, Cassandra Slader, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Kevin Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes, (unknown)	2012	14
17	Primary central nervous system lymphoma: epidemiology and clinical presentation Kun-Wei Song, Samar Issa, Tracy T. Batchelor	2021	14
18	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia ·John M. Burke, Richard H. C. Van Der Jagt, Brad S. Kahl, P. Wood, Tim E. Hawkins, David A. Macdonald, Mark Hertzberg, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela C. Munteanu, Timothy W. Victor, Ian W. Flinn	2016	14
19	Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial Neuro-Oncology ·Matthijs van der Meulen, Linda Dirven, Esther J. J. Habets, Katerina Bakunina, Marion Smits, Hakim C. Achterberg, Tatjana Seute, Gavin Cull, Harry C. Schouten, Josée M. Zijlstra, Dieta Brandsma, Roelien H. Enting, Max Beijert, Martin Taphoorn, Martin J. van den Bent, Samar Issa, Jeanette K. Doorduijn, Jacoline E. C. Bromberg	2021	12
20	Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial Blood ·Brad S. Kahl, John M. Burke, Richard van der Jagt, Julie E Chang, P. Wood, Tim E. Hawkins, David A. Macdonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, Ian W. Flinn	2017	10

About Samar Issa

Samar Issa is a scholar working on Neurology, Genetics, Pathology and Forensic Medicine, Hematology and Oncology, having authored 43 papers that have together received 1.7k indexed citations. Recurring topics across this work include CNS Lymphoma Diagnosis and Treatment (23 papers), Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (6 papers), Glioma Diagnosis and Treatment (5 papers), Acute Lymphoblastic Leukemia research (4 papers), Childhood Cancer Survivors' Quality of Life (2 papers) and Viral-associated cancers and disorders (2 papers). The work is most often cited by research in Genetics (796 citations), Pathology and Forensic Medicine (1.2k citations), Neurology (765 citations), Oncology (596 citations) and Hematology (106 citations). Samar Issa has collaborated with scholars based in New Zealand, Australia and United States. Frequent co-authors include David Simpson, P. Wood, Kathryn S. Kolibaba, John M. Burke, David A. Macdonald, Ian W. Flinn, Tim E. Hawkins, Brad S. Kahl, Richard van der Jagt and Doreen M. Hallman. Their work appears in journals such as Blood, Hematological Oncology, Neuro-Oncology, Journal of Clinical Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Samar Issa

Impact in

Papers in i

In The Last Decade

Samar Issa

Samar Issa's Hit Papers

Peers

Countries citing papers authored by Samar Issa

Fields of papers citing papers by Samar Issa

All Works

About Samar Issa

Explore authors with similar magnitude of impact

Papers in